newsfilter
← Latest News
Business Wire·

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

-- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which demonstrated 97% ORR and 62% CR/sCR at a median follow-up of